(Palivizumab)Biosimilar Reference Antibody-GS40527 新品

货号：GS40527

Palivizumab is a humanized monoclonal antibody of the IgG1κ isotype that targets the fusion (F) glycoprotein of respiratory syncytial virus (RSV). It binds to a conserved epitope on the F protein, preventing viral fusion with host respiratory epithelial cells and thereby neutralizing RSV. Palivizumab is approved for the prophylaxis of severe lower respiratory tract disease caused by RSV in high‑risk infants and young children, including those born prematurely (≤35 weeks gestational age) or with chronic lung disease (bronchopulmonary dysplasia) or significant congenital heart disease. It is administered via intramuscular injection monthly during the RSV season.